Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis.

Jessica K SullivanPaul P FaheyKinglsey E AghoSimon P HurleyZhihui FengRichard O DayDavid Lim

Published in: Neuro-oncology practice (2022)

This review suggests that glioma patients undergoing RT may experience prolonged survival due to HDACi VPA administration. Further randomized controlled trials are required to validate these findings. Additionally, more research into the use of HDACi radio-adjuvant treatment in non-glioma solid organ malignancies is warranted.

Keyphrases

patients undergoing
randomized controlled trial
early stage
systematic review
free survival
combination therapy
replacement therapy
meta analyses